Analysts Set Catalent, Inc. (NYSE:CTLT) PT at $53.14

Shares of Catalent, Inc. (NYSE:CTLT) have been assigned an average recommendation of “Hold” from the twelve research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $53.14.

A number of research firms have commented on CTLT. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, February 20th. Stephens reiterated an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a report on Thursday, April 4th. Finally, StockNews.com began coverage on Catalent in a report on Thursday, June 6th. They set a “sell” rating for the company.

Insider Activity

In related news, insider Ricky Hopson sold 1,401 shares of Catalent stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the sale, the insider now directly owns 20,617 shares in the company, valued at $1,118,678.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.31% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Catalent

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Catalent by 1.8% in the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock valued at $931,909,000 after purchasing an additional 365,648 shares during the period. Capital World Investors grew its position in shares of Catalent by 6.1% in the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock valued at $857,264,000 after purchasing an additional 1,098,474 shares in the last quarter. Nomura Holdings Inc. lifted its holdings in Catalent by 149.4% during the 4th quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock worth $516,126,000 after purchasing an additional 6,881,914 shares in the last quarter. Cadian Capital Management LP boosted its stake in Catalent by 14.3% in the 4th quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock worth $272,473,000 after purchasing an additional 759,600 shares during the period. Finally, Ameriprise Financial Inc. grew its holdings in Catalent by 65.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company’s stock valued at $158,601,000 after buying an additional 1,384,313 shares in the last quarter.

Catalent Price Performance

CTLT stock opened at $55.95 on Monday. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. The company’s fifty day simple moving average is $55.70 and its 200 day simple moving average is $52.42. Catalent has a 12-month low of $31.80 and a 12-month high of $60.20. The firm has a market cap of $10.13 billion, a price-to-earnings ratio of -9.17, a PEG ratio of 6.66 and a beta of 1.20.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.11 billion. On average, analysts expect that Catalent will post 0.28 earnings per share for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.